DIRECTORS

The Board consists of nine Directors, including three executive Directors, three non-executive Director and three independent non-executive Directors. Pursuant to the Articles of Association, our Directors are appointed for a term of three years and may be re-elected for successive re-appointments. The Board is responsible for and has the general power over the management and operation of our business, including determining our business strategies and investment plans, implementing resolutions passed at our Shareholders' general meetings, and exercising other powers, functions and duties as conferred by the Articles of Association. The Board also assumes the responsibilities for developing and reviewing the policies and practices of our Company on corporate governance, risk management and internal control and compliance with legal and regulatory requirements. The following table sets forth the key information about our Directors.

Name	Age	Position	Responsibilities	Date of first appointment as a Director	Date of joining the Group
Mr. Luo Zhigang (羅志剛)	[56]	Chairman of the Board and non-executive Director	Responsible for advising our Group on overall strategic planning and business management	January 6, 2021	January 2021
Mr. Wu Xiaoming (吳曉明)	[51]	Executive Director and general manager	Responsible for overall business direction, day-to-day management of our Group, radiopharmaceutical research and development and manufacturing	July 19, 2023	January 2021
Mr. Liu Xiaojie (劉曉傑)	[44]	Non-executive Director	Providing professional opinion and judgment to our Board	November 19, 2024	November 2024
Ms. You Sai (由賽)	[40]	Non-executive Director	Providing professional opinion and judgment to our Board	July 19, 2023	July 2023
Mr. Li Ji (李季)	[35]	Executive Director, Board secretary and joint company secretary	Responsible for corporate governance, internal control, investor relations, information disclosure of the Group and capital market affairs, management of investment and financing and providing support and assistance to meetings of the Board and shareholders	November 19, 2024	January 2021
Mr. Yuan Chunyun (袁春雲)	[33]	Executive Director and financial director	Responsible for overall financial management of our Group	July 4, 2025	October 2024
Mr. Zhang Yongxue (張永學)	[73]	Independent non-executive Director	Providing independent opinion and judgment to the Board	September 18, 2025	September 2025
Dr. Li Yaming (李亞明)	[65]	Independent non-executive Director	Providing independent opinion and judgment to the Board	September 18, 2025	September 2025
Mr. Fan Chi Chiu (范智超)	[40]	Independent non-executive Director	Providing independent opinion and judgment to the Board	September 18, 2025	September 2025

Executive Directors and Non-Executive Directors

Mr. Luo Zhigang (羅志剛), aged [56], joined our Group in January 2021 and served as a Director of our Company from January 2021 to September 2025. Mr. Luo was appointed as the chairman of the Board of our Company in July 2023. He was re-designated as our non-executive Director in September 2025. He is primarily responsible for advising our Group on overall strategic planning and business management. Mr. Luo has also been serving as a director of LNC PHARMA PTE. LTD. since August 2022.

Mr. Luo served as a chief technician at Military General Hospital of Beijing PLA (北京軍區總醫院) from December 1988 to January 2003. He served as a manager and deputy general manager at Beijing AMS Electronics Co., Ltd. (北京安迪科電子有限責任公司) from October 2003 to March 2006. From March 2006 to November 2024, Mr. Luo served as the general manager of Nanjing JYAMS. Mr. Luo served as the deputy general manager of Dongcheng Biochem from August 2018 to December 2021 and has been serving as the general manager of Dongcheng Biochem since December 2021.

Mr. Luo obtained his bachelor's degree in medical imaging engineering from Guangzhou First Military Medical University of the People's Liberation Army of China (中國人民解放軍第一軍醫大學) (currently known as Southern Medical University (南方醫科大學)) in the PRC in July 1992 and his master's degree in business administration from Beijing University of Posts and Telecommunications (北京郵電大學) in the PRC in April 2003.

Mr. Wu Xiaoming (吳曉明), aged [51], joined our Group and served as general manager since January 2021. Mr. Wu served as a Director of our Company since July 2023. Mr. Wu was re-designated as an executive Director in September 2025 and continued to serve as the general manager of our Company. He is primarily responsible for overall business direction, day-to-day management of our Group, radiopharmaceutical research and development and manufacturing. Mr. Wu has also been serving as a director of LNC PHARMA PTE. LTD. since August 2022.

Mr. Wu has over 20 years of experience in the drug development and drug registration management industry. From June 2001 to June 2003, Mr. Wu worked at Hefei Jiuwangli Pharmaceutical Co., Ltd. (合肥市九萬里醫藥有限公司). Mr. Wu previously worked at Anhui Pioneer Pharmaceutical Co., Ltd. (安徽省先鋒醫藥有限公司) from July 2003 to March 2017. Mr. Wu worked at Beijing Shangzhi Compliance Technology Co., Ltd. (北京尚質合規科技有限公司) from April 2017 to August 2018. He served at Dongcheng Biochem, where he has held various positions, including the manager of drug registration and compliance department from September 2018 to August 2023, vice president of innovation research institute from May 2019 to August 2025 and the deputy general manager from January 2021 to August 2025.

Mr. Wu obtained his bachelor's degree in biochemistry from Anhui University (安徽大學) in the PRC in July 1995 and his master's degree in engineering project management from Peking University (北京大學) in the PRC in June 2014.

Mr. Liu Xiaojie (劉曉傑), aged [44], joined our Group in November 2024 and served as a Director of our Company. Mr. Liu was re-designated as a non-executive Director of our Company in September 2025. He is primarily responsible for providing professional opinion and judgment to our Board.

From September 2007 to March 2009, Mr. Liu worked at Shandong Dashun Tiancheng Property Co., Ltd. (山東大舜天成置業有限公司). Since November 2009, he has served various positions in Dongcheng Biochem, including the securities representative, general manager of the active pharmaceutical ingredient (API) division, deputy chief financial officer for API operations and deputy general manager. He is currently the director, secretary of the board of directors of Dongcheng Biochem.

Mr. Liu obtained his bachelor's degree in finance from Shandong Institute of Economics (山東經濟學院) (currently known as Shandong University of Finance and Economics (山東財經大學)) in the PRC in July 2005. He also obtained the certificate of the secretary of the board from Shenzhen Stock Exchange in July 2012 and has been a non-practicing member of The Chinese Institute of Certified Public Accountants since December 2009.

Ms. You Sai (由賽), aged [40], joined our Group in July 2023 and served as a Director. She was re-designated as a non-executive Director of our Company in September 2025. She is primarily responsible for providing professional opinion and judgment to our Board.

Ms. You served as the accounting specialist in Lenovo (Beijing) Co., Ltd. (聯想(北京)有限公司) from March 2011 to June 2012. She served as the general manager of Yantai Dongrui Investment Co., Ltd. (煙臺東瑞投資有限公司) from June 2012 to July 2017. Ms. You has been holding multiple managing positions at Dongcheng Biochem successively since August 2017, including the deputy manager of the president's office, the assistant to general manager of formulation marketing center, the president of group operation and vice general manager.

Ms. You obtained her bachelor's degree in biological science from Yantai University (煙臺大學) in the PRC in June 2008 and her master's degree in accounting and information management from The University of Texas at Dallas in the United States in May 2010.

Mr. Li Ji (李季), aged [35], joined our Group in January 2021 and served as a supervisor of the Company from January 2021 to December 2024. He resigned as a supervisor and was appointed as a Director in November 2024 and has served as the Board secretary since November 2024. He was re-designated as an executive Director in September 2025. Mr. Ji was also appointed as and the joint company secretary of the Company on September 2025, with effect upon [**REDACTED**]. He is primarily responsible for corporate governance, internal control, investor relations, information disclosure of the Group and capital market affairs, management of investment and financing and providing support and assistance to meetings of the Board and shareholders.

Mr. Li worked at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥集團股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 1276) and the Shanghai Stock Exchange (stock code: 600276) from July 2014 to April 2017. From April 2017 to August 2025, Mr. Li worked at the securities department of Dongcheng Biochem with his last position as the securities representative of Dongcheng Biochem from October 2020 to August 2025.

Mr. Li obtained his bachelor's degree in pharmaceutical science from Anhui University of Science and Technology (安徽理工大學) in the PRC in June 2014. He obtained the certificate of the secretary of the board from the Shenzhen Stock Exchange in September 2020.

Mr. Yuan Chunyun (袁春雲), aged [33], joined our Group and has served as the financial director of our Company since October 2024. Mr. Yuan was appointed as a Director in July 2025. He was re-designated as an executive Director in September 2025. He is primarily responsible for overall financial management of our Group.

Mr. Yuan worked at CRRC Qishuyan Locomotive and Rolling Technology Research Institute Co., Ltd. (中車戚墅堰機車車輛工藝研究所有限公司) from September 2016 to March 2017. He worked at BDO China Shu Lun Pan CPAs (立信會計師事務所(特殊普通合夥)) with his last position as the the senior project manager from April 2017 to January 2023. Mr. Yuan also served as the finance manager of Dongcheng Biochem from February 2023 to August 2024.

Mr. Yuan obtained his bachelor's degree in financial management from Nanjing University of Science and Technology (南京理工大學) in the PRC in June 2016.

Independent Non-Executive Directors

Mr. Zhang Yongxue (張永學), aged [73], was appointed as an independent non-executive Director of our Company in September 2025. He is primarily responsible for providing independent opinion and judgment to the Board.

Mr. Zhang have nearly fifty years of experience in clinical research and development of radiopharmaceutics and nuclear medicine. Mr. Zhang is serving as the chief physician of the Department of Nuclear Medicine of Peking University Shenzhen Hospital (北京大學深圳醫院) and the director of Nuclear Medicine Quality Control Center of Hubei Province (湖北省核醫學質控中心主任). Mr. Zhang worked at Union Hospital Tongji Medical College Huazhong University of Science and Technology (華中科技大學同濟醫學院附屬協和醫院) from December 1987 to January 2016, where he has held various positions, including chief physician, associate professor, professor and the head of nuclear medicine department. Mr. Zhang has been qualified as the doctoral supervisor and the level-2 professor of Union Hospital Tongji Medical College Huazhong University of Science and Technology since 1998 and 2010, respectively. In addition, Mr. Zhang also held certain positions in academic institutions including the deputy chairman at Chinese Society of Nuclear Medicine (中華醫學會核醫學分會副主任委員) and the president of the Nuclear Medicine Branch of Chinese Nuclear Society (中國核學會核醫學分會理事長).

Mr. Zhang obtained his bachelor's degree in medicine from Wuhan Medical College (武漢醫學院) (currently known as Huazhong University of Science and Technology (華中科技大學同濟醫學院)) in the PRC in July 1974.

Dr. Li Yaming (李亞明), aged [65], was appointed as an independent non-executive Director of our Company in September 2025. He is primarily responsible for providing independent opinion and judgment to the Board.

Dr. Li Yaming has been engaged in nuclear medicine clinical practice, teaching, and both basic and translational research since December 1983 and has extensive experience in nuclear imaging, radionuclide therapy, and academic leadership in the field. Dr. Li serves as a second-level professor (二級教授) and chief physician (主任醫師) of the Department of Nuclear Medicine at the First Affiliated Hospital of China Medical University. Dr. Li is a doctoral supervisor (博士研究生導師) and a leading figure in imaging sciences at China Medical University (中國醫科大學影科帶頭人). He also serves as a member of the Academic Degree Committee (學位委員會委員) and the Academic Committee (學術委員會委員) of China Medical University.

Dr. Li obtained his bachelor's degree in medicine from China Medical University in the PRC in August 1983. He obtained his master's degree in nuclear medicine from Tongji Medical College (同濟醫科大學) (currently known as Tongji Medical College of Huazhong University of Science & Technology (華中科技大學同濟醫學院)) in the PRC in June 1989. Dr. Li obtained his doctoral degree in nuclear medicine from Shanghai Second Medical University (上海第二醫科大學) (currently known as Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院)) in the PRC in June 1997.

Mr. Fan Chi Chiu (范智超), aged [40], was appointed as an independent non-executive Director of our Company in September 2025. He is primarily responsible for providing independent opinion and judgment to the Board.

Mr. Fan has over 15 years of experience in accounting, corporate finance and investment. Mr. Fan joined PricewaterhouseCoopers Ltd. as an associate in assurance department and was promoted to the senior associate from October 2009 to June 2011. From July 2011 to February 2014, he worked as an analyst at Barclays Capital Asia Limited. From April 2014 to March 2015, he served as the financial director of Vantasia Holdings (HK) Limited (萬安(香港)有限公司). From April 2015 to September 2021, he served as the chief financial officer of ELL Environmental Holdings Limited (強泰環保控股有限公司) (stock code: 1395). From July 2017 to September 2021, Mr. Fan served as an executive director of Grace Wine Holdings Limited (怡園酒業控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 8146). Mr. Fan has been serving as the chief investment officer of AB Builders Group Limited (奧邦建築集團有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 1615), since November 2021.

Mr. Fan also holds multiple directorship positions in several listed companies listed on the Hong Kong Stock Exchange. Since June 2019, Mr. Fan has served as an independent non-executive director of Hevol Services Group Company Limited (和泓服務集團有限公司) (stock code: 6093) and Shinelong Automotive Lightweight Application Limited (勛龍汽車輕量化應用有限公司) (stock code: 1930) respectively. He has also served as an independent non-executive director of Weihai City Commercial Bank Company Limited (威海市商業銀行股份有限公司) (currently known as Weihai Bank Co., Ltd. (威海銀行股份有限公司)) (stock code: 9677) since June 2020.

Mr. Fan obtained a bachelor's degree in business administration, with major in professional accountancy from the Chinese University of Hong Kong in December 2007. Mr. Fan has been a member of the Hong Kong Institute of Certified Public Accountants since January 2011.

SENIOR MANAGEMENTS

The senior management is comprised of three members who are responsible for our day-to-day management and operation. The following table sets forth the key information about our senior management.

Name	Age	Position	Responsibilities	Date of appointment as Senior Management	Date of joining the Group
Mr. Wu Xiaoming (吳曉明)	[51]	Executive Director and general manager	Responsible for overall business direction, day-to-day management of our Group, radiopharmaceutical research and development and manufacturing	January 6, 2021	January 2021
Mr. Li Ji (李季)	[35]	Executive Director and Board secretary	Responsible for corporate governance, internal control, investor relations, information disclosure of the Group and capital market affairs, management of investment and financing and providing support and assistance to meetings of the Board and shareholders	November 19, 2024	January 2021
Mr. Yuan Chunyun (袁春雲)	[33]	Executive director and financial director	Responsible for overall financial management of our Group	October 1, 2024	October 2024

For the biographies of the members of Mr. Wu, Mr. Li and Mr. Yuan, please refer to "— Executive Directors and Non-Executive Directors" of this section.

GENERAL

As of the Latest Practicable Date, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries,

(i) save as disclosed above, none of the Directors or members of the senior management has held any directorship in any public company the securities of which are listed on any securities market in Hong Kong or overseas during the three years immediately preceding the date of this Document;

(ii) save as disclosed above, none of the Directors or members of the senior management of the Company was related to any other Directors and members of the senior management;

(iii) save as disclosed in "Relationship with our Controlling Shareholders," "Substantial Shareholders" and "Appendix IV — Statutory and General Information" to this Document, none of the Directors or general manager of the Company held any interest in the Shares which would be required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance; and

(iv) there was no additional matter with respect to the appointment of the Directors that needs to be brought to the attention of the Shareholders, and there was no additional information relating to the Directors that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our Company's business which would require disclosure under Rule 8.10 of the Listing Rules.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in September 2025, and (ii) understands his or her obligations as a director of a [**REDACTED**] issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he/she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointments.

JOINT COMPANY SECRETARIES

Mr. Li Ji (李季), aged [35], was appointed as the joint company secretary of our Company in September 2025 with effect upon [**REDACTED**]. Please refer to "— Executive Directors and Non-Executive Directors" in this section for the biographical details of Mr. Li.

Ms. Zheng Hongyi (鄭泓懌), was appointed as our joint company secretary in March 2026. She is a manager of SWCS Corporate Services Group (Hong Kong) Limited and has over 6 years of experience in corporate secretary and corporate finance. Ms. Zheng is a fellow member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ms. Zheng holds dual master's degrees in both International Relations and Public Policy from the University of Macau in Macau in July 2019, and Corporate Governance and Compliance from the Open University of Hong Kong (香港公開大學) (currently known as The Hong Kong Metropolitan University (香港都會大學)) in Hong Kong in September 2024.

BOARD COMMITTEES

Our Board delegates certain responsibilities to various committees. In accordance with the relevant PRC laws and regulations and the Corporate Governance Code as set out in the Appendix C1 to the Listing Rules, our Company has formed four Board committees, namely the Audit Committee, the Remuneration and Appraisal Committee, the Nomination Committee and the Strategy Committee.

Audit Committee

We have established an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of Part 2 of the Corporate Governance Code. The Audit Committee consists of three Directors, namely Mr. Fan Chi Chiu, Mr. Li Yaming, and Ms. You Sai. Mr. Fan Chi Chiu, who possesses the appropriate professional accounting and related financial management expertise as required under Rules 3.10(2) and 3.21 of the Listing Rules, serves as the chairperson of the Audit Committee. The primary duties of the Audit Committee include, but are not limited to, reviewing the Company's financial information and its disclosure, and monitoring and evaluating internal and external audit work and internal controls.

Remuneration and Appraisal Committee

We have established a Remuneration and Appraisal Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph E.1 of Part 2 of the Corporate Governance Code. The Remuneration and Appraisal Committee consists of five Directors, namely Mr. Li Yaming, Mr. Fan Chi Chiu, Mr. Zhang Yongxue, Mr. Wu Xiaoming and Ms. You Sai. Mr. Li Yaming serves as the chairperson of the Remuneration and Appraisal Committee. The primary duties of the Remuneration and Appraisal Committee include, but are not limited to, formulating evaluation standards for our Directors and senior management of the Company, implementation of measures in response to such evaluation, and formulating and reviewing the remuneration policies and plans for Directors and senior management of the Company.

Nomination Committee

We have established a Nomination Committee with written terms of reference in compliance with Rule 3.27A of the Listing Rules and paragraph B.3 of Part 2 of the Corporate Governance Code. The Nomination Committee consists of three Directors, namely Mr. Zhang Yongxue, Dr. Li Yaming and Ms. You Sai. Mr. Zhang Yongxue serves as the chairperson of the Nomination Committee. The primary duties of the Nomination

Committee include, but are not limited to, developing standards and procedures for the election of our Directors and senior management of the Company, selecting and examining the qualifications of the candidates for our Directors and senior management of the Company, and reviewing the structure, size and composition of the Board at least annually, assist the Board in maintaining a board skills matrix and making recommendations on any proposed changes to our Board.

Strategy Committee

We have established a Strategy Committee consisting of three Directors, namely Mr. Luo Zhigang, Mr. Wu Xiaoming, Ms. You Sai with Mr. Luo Zhigang currently serving as the chairperson. The primary duties of the Strategy Committee include, but are not limited to, conducting research and making recommendations on our Company's long-term development plans, business strategies and objectives, and major strategic investment and financing proposals.

CORPORATE GOVERNANCE CODE

The Company is committed to achieving a high standard of corporate governance with a view to safeguarding the interests of our Shareholders. To accomplish this, the Company intends to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules after the [**REDACTED**]. The Company intends to comply with all code provisions under the Corporate Governance Code after the [**REDACTED**].

BOARD DIVERSITY POLICY

We have adopted the board diversity policy which sets out the objective and approach for achieving and maintaining the diversity of the Board in order to enhance its effectiveness. In accordance with the board diversity policy, the Company seeks to achieve board diversity by taking into account a number of factors, including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and/or length of service. The ultimate selection of Board candidates will be based on merit and potential contribution to our Board having due regard to the benefits of diversity on the Board and also the specific needs of the Company without focusing on a single diversity aspect. Our Directors have a balanced mix of knowledge and skills, including overall management and strategic development as well as knowledge and experience in areas such as medicine and pharmaceutical research. They obtained degrees in various areas including, among others, medicine, biological science, finance, management and accounting. Furthermore, our Board has a diverse age and gender representation. Our Board currently comprises one female Directors and eight male Directors, ranging from [32] years old to [72] years old.

With regards to gender diversity on the Board, we recognize the particular importance of gender diversity. Our board diversity policy provides that our Board should aim to increase the proportion of female members to more than one female member over time after [**REDACTED**] where possible when selecting and making recommendations on suitable candidates for Board appointments. We have taken and will continue to take steps to promote and enhance gender diversity at all levels of the Company, including but without limitation at our Board and senior management levels. We will maintain a focus on gender diversity when recruiting staff at the mid to senior level so as to develop a pipeline of potential female successors to our Board. The Group will also identify and select several female individuals with a diverse range of skills, experience and knowledge in different fields from time to time, and maintain a list of such female individuals who possess qualities to become our Board members, which will be reviewed by our nomination committee periodically to maintain gender diversity of our Board. Taking into account our existing business model and specific needs as well as the different background of our Directors, the composition of our Board satisfies the board diversity policy.

Upon the [**REDACTED**], the Nomination Committee will from time to time discuss and agree on expected goals to ensure board diversity, and review and, where necessary, update the board diversity policy to ensure that the policy remains effective. The Company will disclose the biographical details of each Director and report on the implementation of the board diversity policy (including whether we have achieved board diversity) in its annual corporate governance report.

PRE-[REDACTED] EQUITY INCENTIVE PLANS

We adopted the Pre-[**REDACTED**] Equity Incentive Plans, details of which are set forth in "Appendix IV — Statutory and General Information — Pre-[**REDACTED**] Equity Incentive Plans" to this Document.

DIRECTORS' AND GENERAL MANAGER'S REMUNERATION AND REMUNERATION OF THE FIVE HIGHEST-PAID INDIVIDUALS

The Directors and senior management members who receive remuneration from the Company are paid in the forms of salaries, bonuses, allowances and benefits in kind, equity-settled share award expense and pension scheme contributions. Our independent non-executive Directors receive compensation based on their responsibilities. The remuneration of the Directors and senior management members is determined with reference to the remuneration paid by comparable companies and the achievement of major operating indicators of the Company.

The aggregate amount of remuneration (including salaries, bonuses, allowances and benefits in kind, equity-settled share award expense and pension scheme contributions) paid to the Directors for the two years ended December 31, 2024 and 2025 amounted to RMB4.9 million and RMB5.8 million, respectively.

The five highest paid individuals of our Group in the two years ended December 31, 2024 and 2025 included 1 and 2 Directors, respectively. The aggregate amount of remuneration (including salaries, bonuses, allowances and benefits in kind, equity-settled share award expense and pension scheme contributions) incurred by the five highest-paid individuals of the Group (excluding Directors) for the two years ended December 31, 2024 and 2025 amounted to RMB2.7 million and RMB3.9 million, respectively.

Under the current compensation arrangement, we estimate the total compensation before taxation, including estimated share-based compensation, to be accrued to our Directors for the year ending December 31, 2026 to be approximately RMB5.2 million. The actual remuneration of Directors in 2026 may be different from the expected remuneration.

During the Track Record Period, no remuneration was paid by the Company to, or receivable by, our Directors or the five highest paid individuals as an inducement to join or upon joining the Company or as compensation for loss of office in connection with the management positions of the Company or any subsidiary of the Company.

During the Track Record Period, none of our Directors waived any remuneration.

COMPLIANCE ADVISER

The Company has appointed Patrons Capital Limited as our Compliance Adviser in compliance with Rules 3A.19 and 3A.32 of the Listing Rules. The Compliance Adviser will provide us with guidance and advice as to compliance with the Listing Rules and other applicable laws, rules, codes and guidelines.

Pursuant to Rule 3A.24 of the Listing Rules, the Compliance Adviser will, on a timely basis, inform the Company of any amendment or supplement to the Listing Rules that are announced by the Stock Exchange. The Compliance Adviser will also inform the Company of any new or amended law, regulation or code in Hong Kong applicable to us, and advise us on the continuing requirements under the Listing Rules and applicable laws and regulations. The term of the appointment will commence on the [**REDACTED**] and is expected to end on the date on which the Company complies with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [**REDACTED**].